Literature DB >> 29605211

Spirometric impairments, cardiovascular outcomes, and noncardiovascular death in older persons.

Carlos A Vaz Fragoso1, Peter H Van Ness2, Terrence E Murphy2, Gail J McAvay2.   

Abstract

BACKGROUND: In prior work involving older persons, the reported associations of spirometric impairments with cardiovascular outcomes may have been confounded by age-related changes in lung function. Hence, using more age-appropriate spirometric criteria from the Global Lung Function Initiative (GLI), we have evaluated the associations of spirometric impairments, specifically restrictive-pattern and airflow-obstruction, with cardiovascular death (CV-death) and hospitalization (CV-hospitalization). In these analyses, we also evaluated the competing outcome of noncardiovascular death (nonCV-death) and calculated measures of relative and absolute risk.
METHODS: Our study sample was drawn from the Cardiovascular Health Study (CHS), including 4232 community-dwelling white persons aged ≥65 years. Multivariable regression models included the following baseline predictors: GLI-defined restrictive-pattern and airflow-obstruction, age, male gender, obesity, waist circumference, current smoker status, ≥10 pack-years of smoking, hypertension, dyslipidemia, diabetes, and cardiovascular and cerebrovascular disease. Outcomes included adjudicated CV-death, CV-hospitalization, and nonCV-death, ascertained over 10 years of follow-up. Measures of association included hazard ratios (HRs), rate ratios (RRs), and average attributable fraction (AAF), each with 95% confidence intervals.
RESULTS: Restrictive-pattern and airflow-obstruction were associated with CV-death (adjusted HRs: 1.57 [1.18, 2.09] and 1.29 [1.04, 1.60]) and with nonCV-death (adjusted HRs: 2.10 [1.63, 2.69] and 1.79 [1.51, 2.12]), respectively. Airflow-obstruction, but not restrictive-pattern, was also associated with CV-hospitalization (adjusted RRs: 1.18 [1.02, 1.36] and 1.20 [0.96, 1.50], respectively). The adjusted AAFs of restrictive-pattern and airflow-obstruction were 1.68% (0.46, 3.06) and 2.35% (0.22, 4.72) for CV-death, and 3.44% (1.97, 5.08) and 7.77% (5.15, 10.60) for nonCV-death, respectively.
CONCLUSION: Assessment of GLI-defined spirometric impairments contributes to broad geriatric risk stratifications for both cardiovascular and non-cardiovascular outcomes.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29605211      PMCID: PMC5881905          DOI: 10.1016/j.rmed.2018.02.018

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  46 in total

1.  Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not < 70%.

Authors:  James E Hansen; Xing-Guo Sun; Karlman Wasserman
Journal:  Chest       Date:  2007-02       Impact factor: 9.410

2.  Spirometry, Static Lung Volumes, and Diffusing Capacity.

Authors:  Carlos A Vaz Fragoso; Hilary C Cain; Richard Casaburi; Patty J Lee; Lynne Iannone; Linda S Leo-Summers; Peter H Van Ness
Journal:  Respir Care       Date:  2017-07-11       Impact factor: 2.258

3.  Forced vital capacity paired with Framingham Risk Score for prediction of all-cause mortality.

Authors:  H M Lee; H Le; B T Lee; V A Lopez; N D Wong
Journal:  Eur Respir J       Date:  2010-06-18       Impact factor: 16.671

4.  Deaths observed in Medicare beneficiaries: average attributable fraction and its longitudinal extension for many diseases.

Authors:  T E Murphy; G McAvay; N J Carriero; C P Gross; M E Tinetti; H G Allore; H Lin
Journal:  Stat Med       Date:  2012-03-13       Impact factor: 2.373

5.  Phenotype of normal spirometry in an aging population.

Authors:  Carlos A Vaz Fragoso; Gail McAvay; Peter H Van Ness; Richard Casaburi; Robert L Jensen; Neil MacIntyre; Thomas M Gill; H Klar Yaggi; John Concato
Journal:  Am J Respir Crit Care Med       Date:  2015-10-01       Impact factor: 21.405

6.  Respiratory muscle strength and the risk of incident cardiovascular events.

Authors:  J van der Palen; T D Rea; T A Manolio; T Lumley; A B Newman; R P Tracy; P L Enright; B M Psaty
Journal:  Thorax       Date:  2004-12       Impact factor: 9.139

7.  Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study.

Authors:  D J Hole; G C Watt; G Davey-Smith; C L Hart; C R Gillis; V M Hawthorne
Journal:  BMJ       Date:  1996-09-21

8.  Association of FVC and total mortality in US adults with metabolic syndrome and diabetes.

Authors:  Hwa Mu Lee; Sarah J Chung; Victor A Lopez; Nathan D Wong
Journal:  Chest       Date:  2009-05-08       Impact factor: 9.410

9.  Reduced lung function, C-reactive protein, and increased risk of cardiovascular mortality.

Authors:  Kyoung-Bok Min; Jin-Young Min
Journal:  Circ J       Date:  2014-06-30       Impact factor: 2.993

Review 10.  Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis.

Authors:  Katherine M Flegal; Brian K Kit; Heather Orpana; Barry I Graubard
Journal:  JAMA       Date:  2013-01-02       Impact factor: 56.272

View more
  6 in total

1.  Re-evaluation of the Uplift Clinical Trial Using Age-Appropriate Spirometric Criteria.

Authors:  Carlos A Vaz Fragoso; Linda S Leo-Summers; Thomas M Gill; Gail J McAvay
Journal:  Chest       Date:  2020-04-09       Impact factor: 9.410

2.  Re-evaluation of combination therapy in chronic obstructive pulmonary disease (COPD).

Authors:  Carlos A Vaz Fragoso; Thomas M Gill; Linda S Leo-Summers; Peter H Van Ness
Journal:  Respir Med       Date:  2019-03-29       Impact factor: 3.415

3.  FEV1 as a Standalone Spirometric Predictor and the Attributable Fraction for Death in Older Persons.

Authors:  Carlos A Vaz Fragoso; Peter H Van Ness; Gail J McAvay
Journal:  Respir Care       Date:  2019-10-29       Impact factor: 2.258

4.  Diffusing capacity in normal-for-age spirometry and spirometric impairments, using reference equations from the global lung function initiative.

Authors:  Carlos A Vaz Fragoso; Carolyn L Rochester; Gail J McAvay; Lynne Iannone; Linda S Leo-Summers
Journal:  Respir Med       Date:  2020-05-21       Impact factor: 3.415

5.  Factors associated with coronary heart disease in COPD patients and controls.

Authors:  Christina D Svendsen; Karel K J Kuiper; Kristoffer Ostridge; Terje H Larsen; Rune Nielsen; Vidar Hodneland; Eli Nordeide; Per S Bakke; Tomas M Eagan
Journal:  PLoS One       Date:  2022-04-27       Impact factor: 3.752

6.  Relationship between lung function impairment, hypertension, and major adverse cardiovascular events: A 10-year follow-up study.

Authors:  Jiaqi Wang; He Dai; Chong Chen; Ganling Ding; Yongqing Zhang; Yu Qin; Yuqing Zhang; Quanyong Xiang
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-09-16       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.